X-rays miss up to 23% of incidences of lung cancer in the UK,...
- UK study finds chest X-rays fail to spot lung cancer in 23% of cases
- Cancer screenings should be more flexible, says NHS report
- Blood test may replace biopsy in advanced lung cancer
- AI-powered blood test identifies PTSD in early study
- Wolf in sheep’s clothing: clamping down on unauthorised medical devices
Lucence Diagnostics raises $20m to advance liquid biopsy technology
Singapore-based genomic medicine company Lucence Diagnostics has raised $20m in a Series A funding round to commercialise its liquid biopsy technology.
Winterlight Labs raises Series A funds to develop AI vocal technology
Canada-based Winterlight Labs has raised $4.23m (C$5.6m) through a Series A round to develop its artificial intelligence (AI) vocal technology to detect central nervous system disorders and track the efficacy of treatments.
Researchers detect early stage eye melanoma with simple blood test
Researchers at the University of Queensland have found that a simple blood test can help detect melanoma in the eye at an early stage.
Senographe Pristina DBT System
Senographe Pristina is a three-dimensional digital breast tomosynthesis (DBT) system developed by GE Healthcare for the diagnosis and screening of breast disorders in women.
Ikonisys partners with Sheba Medical Center to develop CTC tests
US-based cell diagnostics company Ikonisys has signed a partnership agreement with Israel-based Sheba Medical Center to develop Circulating Tumor Cell (CTC) tests to detect and target specific cancers.
NantHealth gets FDA marketing authorisation for Omics Core assay
US-based NantHealth has received marketing authorisation from the US Food and Drug Administration (FDA) for its Omics Core assay, a whole exome sequencing in vitro diagnostic (IVD) test that can report overall tumour mutational burden (TMB) in cancer tissue.
Thermo Fisher and Owlstone partner for bio marker cancer diagnosis
US-based diagnostics product maker Thermo Fisher Scientific has entered a collaborative partnership with breath biopsy solutions provider Owlstone Medical, for the discovery and validation of new biomarkers by non-invasive breath sampling in order to advance the early diagnosis of cancer and other diseases.
Promega and Merck collaborate to develop MSI CDx for Keytruda use
US-based biotechnology firm Promega has signed a global collaboration deal with Merck to develop its microsatellite instability (MSI) technology as an on-label, solid tumour companion diagnostic (CDx) for Merck’s anti-PD1 immunotherapy pembrolizumab (Keytruda).
Testing Machines and Systems for the Medical Industry
This brochure provides an overview of instruments, machines, systems, and services available from Zwick Roell for testing products from the medical technology and pharmaceutical industries, as well as their use in research and development (R&D), production, quality assurance, and control.
October’s top news stories
3M has completed the acquisition of wound care solutions provider Acelity and its KCI subsidiaries globally for around $6.7bn, and researchers from the Abramson Cancer Center of the University of Pennsylvania have found that liquid biopsy can help to predict the prognosis of glioblastoma(GBM). Medicaldevice-network.com wraps up key headlines from October 2019.
Read our magazine
Medical Technology is the essential reading material for decision-makers in the medical device industry, bringing you the latest news and analysis in an exciting, interactive format.